Navigating Economic Uncertainty in Biopharma

The biopharmaceutical industry clearly isn’t going anywhere, but we’ve been in a downward business cycle. We’ve learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs. The post Navigating Economic Uncertainty in…

Read More

Social Security Praises Its New Chatbot. Ex-Officials Say It Was Tested But Shelved Under Biden.

John McGing couldn’t reach a human. That might be business-as-usual in this economy, but it wasn’t business; he had called the Social Security Administration, where the questions often aren’t generic and the callers tend to be older, disabled, or otherwise vulnerable Americans. McGing, calling on behalf of his son, had an in-the-weeds question: how to…

Read More

Evolution of orphan drug

A study by Fermaglich and Miller (2023) evaluated trends in orphan drug designations and approvals after the Orphan Drug Act of 1983 was passed in the US. The authors use FDA data to evaluate between 1983 and 2022 and find that: Over the 40 years of the ODA, 6,340 orphan drug designations were granted, representing…

Read More